Equator Therapeutics

San Francisco, United States Founded: 2019 • Age: 7 yrs
Mitochondria-targeting drugs are developed to burn calories and boost metabolism.
Annual revenue - Latest available
Total funding $125,000 2 rounds
Employees 3 Tracked headcount
Investors 2 Known backers
Products 2 Services tracked
Competitors 10 Brand Intelligence

About Equator Therapeutics

Equator Therapeutics is a company based in San Francisco (United States) founded in 2019. Equator Therapeutics has raised $125 thousand across 2 funding rounds from investors including HHS and Y Combinator. The company has 3 employees as of December 31, 2024. Equator Therapeutics offers products and services including Thermogenesis Drug and High-Throughput Assays. Equator Therapeutics operates in a competitive market with competitors including Adocia, Altimmune, Carmot, BioAge Labs and Fractyl, among others.

  • Headquarter San Francisco, United States
  • Employees 3 as on 31 Dec, 2024
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Equator Therapeutics
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $125 K (USD)

    in 2 rounds

  • Latest Funding Round
    $1.91 M (USD), Grant

    Sep 20, 2021

  • Investors
    HHS

    & 1 more

  • Employee Count
    3

    as on Dec 31, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Equator Therapeutics

Equator Therapeutics offers a comprehensive portfolio of products and services, including Thermogenesis Drug and High-Throughput Assays.

Product name locked
Category locked
Primary

Stimulates mitochondrial heat production for sustained weight loss.

Product name locked
Category locked
Locked

Identifies compounds for safe thermogenic activation in mitochondria.

People of Equator Therapeutics

Headcount 1-10
Employee Profiles 5
Board Members and Advisors 4
Employee Profiles
People
Junji Suzuki
Director, Japan Branch
People
Yuriy Kirichok
Co-Founder, Chief Scientific Officer
People
Jonah Sinick
Co-Founder & CEO
People
Simon Vu
Scientist

Unlock access to complete

Board Members and Advisors
people
John Amatruda
Scientific Advisor
people
Michael Grabe
Advisor
people
Andrea Dunaif
Advisor
people
Gerald Shulman
Advisor

Unlock access to complete

Funding Insights of Equator Therapeutics

Equator Therapeutics has successfully raised a total of $125K across 2 strategic funding rounds. The most recent funding activity was a Grant round of $1.91 million completed in September 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Equator Therapeutics

Equator Therapeutics has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS and Y Combinator.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Early-stage startups are accelerated via funding and educational programs.
Locked Locked Locked
Public health and human services are overseen by HHS.
Locked Locked Locked
Premium access

Investor details for Equator Therapeutics

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Equator Therapeutics

Investments
Premium access

Investment portfolio details for Equator Therapeutics

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Equator Therapeutics

Premium access

Detailed financials for Equator Therapeutics

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Equator Therapeutics Comparisons

Equator Therapeutics Primary company
Description
Mitochondria-targeting drugs are developed to burn calories ...
Location
San Francisco, United States
Founded Year
2019
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
3
As of 2024
Premium access

Peer comparison for Equator Therapeutics

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Equator Therapeutics

Equator Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adocia, Altimmune, Carmot, BioAge Labs and Fractyl, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Therapeutics for diabetes and obesity treatment are developed.
Locked Locked Locked
Vaccines for infectious diseases and solid tumors are developed.
Locked Locked Locked
Disease-modifying therapies for metabolic diseases are developed.
Locked Locked Locked
Bioinformatics platform is provided for biomarkers and drug discovery.
Locked Locked Locked
Endoscopic procedures for type-2 diabetes treatment are developed.
Locked Locked Locked
Peptide-based therapies for obesity and cardiometabolic disorders are developed.
Premium access

Detailed competitors of Equator Therapeutics

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Equator Therapeutics

Premium access

Complete news archive for Equator Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Equator Therapeutics

Equator Therapeutics was founded in 2019 and raised its 1st funding round 1 year after it was founded.

Equator Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.

Jonah Sinick is the current CEO of Equator Therapeutics.

Equator Therapeutics is a funded company, having raised a total of $125K across 2 funding rounds to date.

As of Dec 31, 2024, the latest employee count at Equator Therapeutics is 3.

Equator Therapeutics was founded in 2019 and is based in San Francisco, United States. Operations focus on the biotechnology sector, where mitochondria-targeting drugs are developed to address metabolic disorders. Research efforts center on enhancing calorie expenditure and improving overall metabolic function through innovative therapeutic approaches. The company is led by CEO Jonah Sinick, with activities conducted primarily in the U.S.

Equator Therapeutics's top competitors include Adocia, BioAge Labs and Fractyl.

Equator Therapeutics offers Thermogenesis Drug and High-Throughput Assays.

Equator Therapeutics has 2 investors. Key investors include HHS, and Y Combinator.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available